Intellia Therapeutics (NTLA) Shareholder Investigation

Shamis & Gentile, P.A. is investigating potential shareholder action claims on behalf of shareholders of Intellia Therapeutics, Inc. ("Intellia Therapeutics" or the "Company") (NTLA) against certain of its directors and officers for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

The law firm is investigating whether Intellia Therapeutics’ board of directors and senior management breached their fiduciary duties to the Company and its shareholders by failing to maintain adequate internal controls and safety-oversight systems for its clinical-stage gene-editing programs.

The investigation focuses on board-level monitoring and regulatory communications related to nexiguran ziclumeran (Nex-Z/NTLA-2001), the Company’s lead CRISPR therapy for ATTR amyloidosis. On October 24, 2025, a trial participant experienced Grade-4 liver toxicity and was hospitalized. Intellia paused dosing and screening across both Phase 3 MAGNITUDE trials on October 27, after which the FDA verbally placed both studies on clinical hold on October 29. The patient later died on November 5, and Intellia publicly disclosed the death and ongoing hold in its November 6, 2025 press release.

Between the first acknowledgment of the hospitalization on October 24, and the day following the disclosure on November 7, Intellia’s stock declined about 63%, from $25.60 to $9.52, resulting in substantial financial and reputational impact.

If you purchased Intellia Therapeutics shares prior to April 3, 2025, and continue to hold them today, you may be able to seek corporate reforms, the return of funds back to the Company, and a court-approved incentive award at absolutely no cost to you.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing shareholder actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including shareholder actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.